A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
A Study of PRT3789 in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) (COPERNICUS)
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence (ELEGANT)
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator’s Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer (rechARge)
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)
Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC)
Phase 2 Open-label Study to Evaluate Momelotinib in Combination with Luspatercept in Participants with Transfusion Dependent Primary or Secondary Myelofibrosis
(EXPANSION) A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally to Patients with Advanced or Metastatic Solid Tumors
A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibitor that Suppresses H3K36me2 in Patients with Relapsed and Refractory Multiple Myeloma
Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (CAMMOUFLAGE Trial)
Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Treatment after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM)
A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
MMRC HORIZON ONE: A PHASE II RANDOMIZED ADAPTIVE PLATFORM TRIAL EVALUATING NOVEL THERAPIES IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
A Phase 3, Randomized, Double-blind, Add-on Study Evaluating the Safety and Efficacy of Navtemadlin Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma
A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell Malignancies.
An Adaptive Phase 3, Randomized, Open-Label, Multicenter Study to Compare the Efficacy and Safety of Axicabtagene Ciloleucel versus Standard of Care Treatment as First-Line Therapy in Subjects with High-Risk Large B-Cell Lymphoma (ZUMA-23)
A Phase 1/2, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies
A PHASE III, MULTICENTER, RANDOMIZED, OPEN‑LABEL STUDY COMPARING THE EFFICACY AND SAFETY OF GLOFITAMAB (RO7082859) IN COMBINATION WITH POLATUZUMAB VEDOTIN PLUS RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE (POLA-R-CHP) VERSUS POLA‑R‑CHP IN PREVIOUSLY UNTREATED PATIENTS WITH LARGE B-CELL LYMPHOMA
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of JNJ-64407564, a Humanized GPRC5D x CD3 DuoBody® Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma
A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared with Investigator’s Choice Monotherapy Treatment in Previously Treated Patients with Incurable, Metastatic/recurrent Head and Neck Squamous Cell Carcinoma
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR – HN1)
A Phase 2 Platform Study of Novel Combination Therapies in Participants with Head and Neck Squamous Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer
A Phase 2, Randomized, Open-label, Platform Study Utilizing a Master Protocol to Evaluate Novel Immunotherapy Combinations in Participants with Previously Untreated, Locally Advanced/Metastatic, Programmed Death Ligand 1-Selected Non-Small-Cell Lung Cancer (GALAXIES LUNG-201)
A Phase III, Open-label, Sponsor-blind, Randomized Study of Dato DXd With or Without Osimertinib Versus Platinum-based Doublet Chemotherapy for Participants with EGFR-mutated Locally Advanced or Metastatic Non-small Cell Lung Cancer whose Disease has Progressed on Prior Osimertinib Treatment (TROPION Lung15)
A randomized, open-label, phase 3 trial comparing the efficacy and safety of OSE2101 versus docetaxel in HLA-A2 positive patients with metastatic Non-Small Cell Lung Cancer (NSCLC) and secondary resistance to Immune Checkpoint Inhibitor (ICI)- ARTEMIA study
A randomized, multicenter, double-blind, Phase 3 study to investigate the safety and efficacy of belrestotug in combination with dostarlimab compared with placebo in combination with pembrolizumab in participants with previously untreated, unresectable, locally advanced or metastatic PD-L1-selected non-small-cell lung cancer (GALAXIES LUNG-301)
A Phase III, Randomized, Double-Blind, Multicenter, Global Study of Rilvegostomig in Combination with Chemotherapy for First-line Treatment of Patients with Metastatic Non-squamous Non-Small Cell Lung Cancer Whose Tumors Express PD-L1 (TC ≥ 1%) (ARTEMIDE-Lung03)
A Phase Ib/III Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)
Phase II, Open-Label, Prospective Single-Arm, Multi-Center Clinical Trial to Evaluate if Adding Venetoclax to Patients on Covalent BTKI for 1L CLL Can Achieve Deep Durable Remissions (BY uMRD 10^-4) to Allow Off-Treatment Period
A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients with Advanced Malignancies
A First-in-Human Study of a Selective FGFR2/3 Inhibitor, CGT4859, in Patients with Cholangiocarcinoma and Other Advanced Solid Tumors
Phase 1/2, Open-label, Multi-center Study of the Safety, Tolerability, and Efficacy of GIM-531 as a Single Agent and in Combination with Anti-PD-1 in Advanced Solid Tumors
First-in-Human, Open-Label, Phase 1/2 Dose-Escalation with Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects with Advanced Solid Malignancies
A Dose-escalation, Dose-finding, and Expansion Study of XL495 as a Single Agent and in Combination Therapy in Participants With Locally Advanced or Metastatic Solid Tumors
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)
A Phase I/II Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in Subjects with Relapsed/Refractory Non-Hodgkin’s Lymphoma or Multiple Myeloma
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to evaluate Dostarlimab as Sequential Therapy after Chemoradiation in Participants with Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma (JADE)
Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan(Dato-DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients With Previously Untreated Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer (TROPION-Breast04)
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigator’s Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Tennessee Oncology Opens New Cancer Clinic in Morristown, Expanding Access to Care in Northeast Tennessee Blog Post
Tennessee Oncology Partners with The Surgical Clinic to Improve Middle Tennesseans Access to World-Class Care Blog Post
Tennessee Oncology and Ascension Saint Thomas Health Revolutionizing Community-Based Blood Cancer Treatments for Middle Tennessee Patients Blog Post
Tennessee Oncology Opens First Radiation Oncology Center in Lebanon Expanding Access to World-Class Cancer Care Blog Post
Tennessee Oncology Expands Subspecialty Services By Adding Two Renowned Gynecological Oncologists Blog Post
Tennessee Oncology Partners Through the McKay Institute with OncoveryCare to Raise $4.5M Seed Round from .406 Ventures Blog Post
Tennessee Oncology Launches Rural Telehealth Program to Bridge Digital Divide for Middle Tennessee Cancer Patients Blog Post
McKay Institute for Oncology Transformation and Penn Center for Cancer Care Innovation Unveil New Collaborative Relationship Blog Post
Nashville State Community College, Tennessee Oncology Form Medical Assistant Certification Program Blog Post
Nashville State Community College, Tennessee Oncology Form Medical Assistant Certification Program Blog Post
Tennessee Oncology Launches the Greco-Hainsworth Tennessee Oncology Centers for Research and Appoints Dr. Ian Flinn as Chief Scientific Officer Blog Post
Examining Colorectal and Cervical Cancer Care in Appalachia : A Review of Barriers and Interventions to Cancer Screening, Genetic Services, and Continuity of Care Blog Post
Tennessee Oncology’s Ashley Todd, Clinical Educator, DNP, RN-BC, OCN®, was published in ONS Voice magazine. Blog Post
We’re Proud to Announce Tennessee Oncology Will Serve Cancer Patients in Cookeville in January. Blog Post
Please join us for our monthly virtual CPAN Advocacy Chat – How 340B in Big Health Systems is Hurting Patients Blog Post
Tennessee Oncology Named One of Nine Oncology Practices Certified Through ASCO Patient-Centered Cancer Care Certification Pilot Blog Post
“It’s a great honor to share my friend ‘Hawk’, a fellow Cadet at the Air Force Academy, on this Memorial Day.” – Amy Cox, Nurse Practitioner, Gallatin Clinic Blog Post
“This Memorial Day I remember the American Heroes I met serving in Bosnia, that made the ultimate sacrifice.” – Howard Burris, M.D. Blog Post
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting Blog Post
Tennessee Oncology Expands Adoption of OncoSmartTM Oncology Optimization Solution by iClinicalOps Blog Post
We are so proud of Dr. Jeff Infante, former Tennessee Oncology physician and key investigator for the Drug Development Unit at Sarah Cannon Research Blog Post
“The pace at which new therapies are moving brings hope that all blood cancer patients in the future will have great options for treatment.” – William Donnellan, M.D. Blog Post
Tennessee Oncology Appoints Dr. Stephen Schleicher as Chief Medical Officer and Promotes Dr. Natalie Dickson to President and Chief Strategy Officer Blog Post
Tennessee Oncology Re-Certified With Perfect Score for High-Quality Cancer Care from the Largest Oncology Association in United States Blog Post
Provision Cares Proton Therapy Nashville Achieves Accreditation From World’s Leading Radiation Oncology Society Blog Post
H3 Biomedicine Presents Investigational Data Update on H3B-6545 for Treatment of Locally Advanced or Metastatic Estrogen Receptor- positive, HER2-negative Breast Cancer at San Antonio Breast Cancer Symposium Blog Post
Tennessee Oncology receives perfect quality score while saving Medicare $5 million during last year of Oncology Care Model Blog Post
Tennessee Oncology and Blue Cross Blue Shield of Tennessee Launch New Value-Based Care Initiative Blog Post
Microsoft’s Iksha Herr to Give Keynote Address at AJMC’s 10th Annual Patient-Centered Oncology Care® Conference Blog Post
New Certification Pilot Focuses on Patient-Centered Cancer Care, Equips Practices with Evidence-based Approach to Value-based Care Delivery Blog Post
Woman carries baby for her twin sister who had hysterectomy due to pregnancy-related cancer Blog Post
Podcast: Dr. F. Anthony Greco Explains How Precision Medicine Has Led to Better Treatments for Cancers of Unknown Origins Blog Post
OneOncology and Tennessee Oncology Present Twelve Posters at ASCO Quality and Care Symposium Blog Post
OneOncology and Tennessee Oncology Partnership Fuels Expansion in Chattanooga with Addition of University Oncology Hematology Associates Blog Post
The Role of the Specialty Pharmacist in Transitioning Patients from Cancer Crisis Care to the Community Blog Post
Tennessee Oncology Chosen To Present Six Posters at the American Society of Clinical Oncology (ASCO) Annual Quality of Care Symposium in San Diego, California. Blog Post
The Future of Healthcare: “Healthcare is far too reactive” with Dr. Jeff Patton of OneOncology and Christina D. Warner Blog Post
The effect of guideline-concordant novel therapy use on meeting cost targets in OCM: Results from a large community oncology network. Blog Post
Lee Schwartzberg tells us how three practices banded together to adapt to today’s cancer care and data revolution Blog Post
Why and When To Get a Mammogram feat. Dr. Erika Hamilton of Tennessee Oncology – WKRN Nashville News 2 Blog Post
General Atlantic Takes Majority Stake in OneOncology, a Startup for Running Cancer-Doctor Practices Blog Post
Sarah Cannon Promotes William Donnellan, MD, to Director, Leukemia/Myelodysplastic Syndrome Research Blog Post
Tennessee Oncology St.Thomas West’s Dr. Kent Shih and Staff, Country Music Artist Jackie Lee, Rolling Stone Magazine and an Evening at the Opry Blog Post
OUR GOAL IS TO MAKE EVERY PATIENT, EVERY FAMILY AND EVERY REFERRING PHYSICIAN SEE THAT HERE, CARING FOR CANCER PATIENTS IS A PRIVILEGE. Blog Post
Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States? Blog Post
The Tennessee Oncology Network Delivers The Most Advanced Care In Every Community We Serve. Blog Post
Rapid infusion of ofatumumab appears safe and reduces infusion related reactions in patients with relapsed/refractory Chronic Lymphocytic Leukemia Blog Post
Summer Is Scorching But The Lifestyle Is Hard To Beat. Leading Practices Embrace Change Because Our Patients Deserve Our Best. Blog Post
The Tennessee Cancer Consortium invites you and a guest to attend Thriving Together: Living Beyond Metastatic Breast Cancer Blog Post
May Is One Fine Month. Nurse Respect. Clinical Trials Close To Home. Honoring Memorial Day. Blog Post
National Women’s Health Week – May 14 – 20, 2017– When Should You Begin Some Common Cancer Screenings? Blog Post
Would You Like To Support Cancer Research And Do Something Good For Your Health? This Blog’s For You. Blog Post
May Is Skin Cancer Prevention and Awareness Month. Know The Good News And How To Protect Yourself From The Bad. Blog Post
Electronic Medical Records, Practice Will Make Perfect- Patience and Diligence Will Get Us There Blog Post
April Is National Minority Health Month. Minority Populations Often Experience Higher Rates Of Disease. Blog Post
Keep your mind clear and uncluttered to keep your energy level high and your focus on what matters most Blog Post
Tennessee Oncology Receives The Oncology Nurse Society (ONS) 2017 Employer Recognition Award Blog Post
Tennessee Oncology Continually Improves Patient Experience. Pilot Study Reduces ER Visits In Patients Receiving IV Chemo. Blog Post
Local breast cancer survivors take to the runway for, “Heroes in Heels Fashion Show at the Factory in Franklin” Blog Post
Genmab Announces U.S. FDA Approval of Arzerra® (ofatumumab) as Extended Treatment for Recurrent or Progressive CLL Blog Post
FDA Approves Expanded Indication for Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Advanced Melanoma Blog Post
BlueCross, Tennessee Oncology Pilot Digital Tools To Improve Care, Experience For Cancer Patients Blog Post
